Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

Biogen advances Alzheimer's tau drug despite missing main trial goal

Biogen advances Alzheimer’s tau program despite midphase miss

Fierce Biotech1 min readAI-assisted summary
Editorial illustration for Biogen advances Alzheimer’s tau program despite midphase miss
Editorial illustration

Summary

Biogen and Ionis Pharmaceuticals have been testing a new drug candidate aimed at treating Alzheimer's disease. The experimental medication targets tau, a protein that forms abnormal tangles in the brains of Alzheimer's patients. However, during a phase 2 study, which is a mid-stage clinical trial used to evaluate a drug's effectiveness, the medication missed its primary endpoint, or main predefined goal.

Researchers had anticipated seeing a clear dose-response relationship, meaning different amounts of the drug would produce predictably different levels of effectiveness, but the trial failed to generate this data. Despite missing the main objective, the drug did show promising signs elsewhere. Researchers observed reductions in the abnormal tau pathology, and the medication yielded cognitive benefits for the patients.

Encouraged by these positive secondary findings, Biogen has committed to moving the candidate forward into registrational development. This means they will conduct the larger, late-stage trials that are required to potentially seek formal regulatory approval for the drug.

Why it matters.

Finding effective treatments for Alzheimer's disease remains one of the greatest challenges in modern medicine. By focusing on clearing tau proteins, Biogen and Ionis are pursuing a vital alternative to other common approaches. If the cognitive benefits observed in this trial can be replicated, this drug could eventually offer a much-needed treatment option to slow mental decline in patients.

However, moving this drug forward is a notable gamble. A major limitation of this advancement is that it relies entirely on secondary observations of cognitive improvement and reduced brain pathology, rather than a clear victory on the trial's primary endpoint. Pressing ahead without the expected dose-response data means the drug will face a strict burden of proof in its upcoming trials to confirm these benefits are real and consistent.

From the source

The story in numbers.

Clinical trial phase
2
Partnering companies involved (Biogen and Ionis)
2
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Biogen advances Alzheimer's tau drug despite missing main trial goal — Daily Strand